Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elsiglutide

Drug Profile

Elsiglutide

Alternative Names: ZP 1846

Latest Information Update: 15 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Helsinn; Zealand Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diarrhoea

Most Recent Events

  • 15 Feb 2019 Elsiglutide is still in phase II trials for Diarrhoea in Belarus, Bulgaria, Czech Republic, Germany, Hungary, Poland, Russia and Ukraine (Zealand Pharma website, February 2019)
  • 12 Jun 2017 Helsinn Healthcare returns its worldwide licensing rights to elsiglutide to Zealand Pharma
  • 02 Jun 2017 Preliminary adverse events data from a phase IIb trial in Diarrhoea presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top